Sierra Oncology, Inc. (SRRA) Social Stream



Sierra Oncology, Inc. (SRRA): $54.99

0.02 (+0.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SRRA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Sierra Oncology Inc (SRRA) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Sierra Oncology Inc.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-08 5 $45 $29 $35.8 $32.05 11.7%
2021-12-17 5 $45 $29 $37 $32.05 15.44%
2022-01-21 5 $45 $32 $37.6 $32.05 17.32%
2022-01-26 5 $45 $32 $38 $32.05 18.56%
2022-03-11 5 $51 $37 $43.6 $32.05 36.04%
2022-03-13 5 $51 $39 $45.2 $32.05 41.03%

The Trend in the Analyst Price Target


Over the past 22 months, SRRA's average price target has gone up $12.53.

Over the past 49 weeks, SRRA's average upside potential has been 62.43%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-04-10 2 32 21 27.75 17.58 57.85%
2021-08-28 2 48 27 33.25 20.86 59.4%
2021-11-30 5 45 29 37.00 23.29 58.87%
2021-12-14 5 45 29 37.00 22.12 67.27%
2021-12-17 5 45 29 37.00 22.50 64.44%

SRRA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 5 0 0 0 0 5

The Trend in the Broker Recommendations


SRRA's average broker recommendation rating improved by 0.5 over the prior 151 days.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for SRRA as an investment opportunity.

  • In the context of all US stocks, Sierra Oncology Inc's number of analysts covering the stock is higher than 195.93% of them.
  • In the context of Pharmaceutical Products stocks, Sierra Oncology Inc's upside potential (average analyst target price relative to current price) is higher than 76.71% of them.
  • In the context of stocks in the small market cap category, Sierra Oncology Inc's average analyst price target is higher than 561.9% of them.
  • To contextualize these metrics, consider that out of Pharmaceutical Products stocks, Sierra Oncology Inc's variance in analysts' estimates is lower than -108.82% of them.

Stocks similar to Sierra Oncology Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are SPRO, SPRB, and SNSE.

Make investment decisions regarding SRRA using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5528 seconds.